Skip to content

Depression research published in 2019

Page 7 of 7: studies 121 to 123 of 123, newest first. Back to the depression overview

Studies

My Dream, My Rules: Can Lucid Dreaming Treat Nightmares?

Frontiers in Psychology 2019 Tainá Carla Freitas De Macêdo, Glescikelly Herminia Ferreira, Katie Moraes De Almondes et al. 65 citations

Nightmares are defined as repeated occurrences of extremely dysphoric and well-remembered dreams that usually involve subjective threats to survival, security, or physical integrity. Generally, they occur during rapid eye movement sleep (REMS) and lead to awakenings with distress and insufficient overnight sleep. Nightmares may occur spontaneously (idiopathic) or as recurrent nightmares....

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.

The American Journal of Drug and Alcohol Abuse 2019 Alan K. Davis, Sara So, Rafael Lancelotta et al. 141 citations

A recent epidemiological study suggested that 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used for spiritual and recreational reasons is associated with subjective improvement in depression and anxiety. Further exploration of the potential psychotherapeutic effects of 5-MeO-DMT could inform future clinical trials. We examined self-reported improvement in depression and anxiety among people who...

[Neurotrophic mechanisms of psychedelic therapy].

Biologie aujourd'hui 2019 Rémi Corne, Raymond Mongeau 7 citations

Psychedelic drugs, often referred to as hallucinogens, are quite distinct from other classes of psychotropic drugs. Although the subjective and behavioral effects they induce are quite dramatic, they possess little addictive potential when compared to nicotine, alcohol or opiates. Since the discovery of ketamine antidepressant effects, there has been growing interest for these molecules....